Hypertrophic cardiomyopathy: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
(46 intermediate revisions by 9 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Genetically-linked (AD) hypertrophy of cardiac muscle - can but does not always cause outflow obstruction | *Genetically-linked (AD) hypertrophy of cardiac muscle - can but does not always cause outflow obstruction | ||
* | *Up to 30% of patients will have no family history<ref>Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force of Practice.</ref> | ||
*Abnormal LV | *Average age of diagnosis between 30-40 years of age | ||
*Diastolic [[heart failure]] | |||
**Abnormal LV function due to decreased compliance | |||
*Historically, obstructive forms known as: | |||
**Idiopathic hypertrophic subaortic stenosis (IHSS) | |||
**Asymmetric septal hypertrophy (ASH) | |||
**Hypertrophic obstructive cardiomyopathy (HOCM) | |||
*Yamaguchi syndrome, an atypical HCOM, in which only 1% are non-Japanese | |||
[[File:Hypertrophic_cardiomyopathy.png|thumb|HOCM]] | |||
== | ==Clinical Features== | ||
*[[Syncope]], [[chest pain]], [[dyspnea]] | |||
*Symptoms made worse by exertion | |||
**Increasing ventricular contractility further narrows outflow as volume is lost | |||
*Systolic [[murmur]] increases with valsalva | |||
**Decreased blood return to heart | |||
**Decreases with squat/fist clench | |||
***Increased peripheral resistance increases aorta and reduces obstruction | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Line 22: | Line 27: | ||
{{Chest Pain DDX}} | {{Chest Pain DDX}} | ||
== | ==Evaluation== | ||
Definitive | *Symptoms: Syncope or sudden death most common | ||
**Also exertional dyspnea, chest pain, syncope, dizziness, palpitations, or [[CHF]] | |||
*Systolic murmur that increases with maneuvers that decrease preload (e.g. valsalva, transitioning from squatting to standing, etc.). | |||
*[[ECG]] | |||
**Nonspecific/normal. | |||
**Or, high voltage/LVH, deep narrow Q waves in 1, avL, V5, V6 = "daggers of death" | |||
[[File:Needle-like q-waves.JPG|thumbnail|Needle-like Q-waves]] | |||
[[File:HOCM Subramaniam.gif|thumbnail|HOCM<ref>http://www.thepocusatlas.com/pediatrics/</ref>]] | |||
===Work-Up=== | |||
*[[ECG]] abnormalities in ~90%, but mostly nonspecific | |||
**High voltage ECG (which may produce abnormal T-waves) | |||
**[[LVH]] | |||
**[[Left atrial enlargement]] | |||
**Tall R-wave in V1, mimicking posterior MI | |||
**"Needle-like" Q waves, especially in lateral leads, mimicking infarction Q waves | |||
*[[CXR]] may be normal as LV is non-dilated | |||
*Echo<ref>Mitevksa IP. Focus on echocardiography in hypertrophic cardiomyopathy - fourth in series. ESC Council for Cardiology Practice. Vol.13,N°20 - 14 Apr 2015.</ref> | |||
**Unexplained wall thickness > 15 mm in any myocardial segment | |||
**Septal/posterior wall thickness ratio: | |||
***>1.3 in normotensive pts | |||
***>1.5 in hypertensive pts | |||
**Systolic anterior motion by M mode in PSL window, worsened by Valsalva | |||
**[[Mitral regurgitation]] | |||
**EF may be preserved until acute decompensation | |||
**Formal echo should include tissue Doppler imaging | |||
==Management== | |||
*Avoid exertion | |||
*ICD +/- pacer for [[ventricular dysrhythmias]] | |||
*Definitive treatment is myomectomy | |||
===Decompensated=== | ===Decompensated=== | ||
*If decompensated presents as hypotensive CHF | *Consider primary insult, which usually is preload issue (fluid depletion, bleed, etc.) | ||
*If decompensated presents as [[cardiogenic shock|hypotensive CHF]] | |||
**Preserve preload | **Preserve preload | ||
***Careful hydration | ***Careful hydration | ||
***Avoid high airway pressure if intubate | ***Avoid high airway pressure if intubate | ||
**Limit tachycardia | **Limit tachycardia | ||
***Beta blockers | ***[[Beta blockers]] | ||
**Avoid vasodilators (no nitrates) | **Avoid vasodilators (''no'' nitrates) | ||
**Maintain sinus | **Maintain sinus rhythm (i.e. cardiovert A. fib) | ||
**Increase afterload (hypotensive only) | **Increase afterload (hypotensive only) | ||
***Phenylephrine | ***[[Phenylephrine]], max dose range depending on source | ||
****Start at 100 mcg/min (~1.5 mcg/kg/min for average adult) | |||
****Range usually 0.5 - 6.0 mcg/kg/min, with efficacy minimal beyond 6 mcg/kg/min)<ref>Global RPH in reference to Micromedex. 12/2014. http://www.globalrph.com/phenylephrine_dilution.htm</ref> | |||
****Max phenylephrine infusion before other pressors | |||
****Fix acid-base disorder as acidosis may prevent pressor efficacy | |||
****Consider maxing [[vasopressin]] next | |||
*****Pressor effects more preserved in hypoxia and acidosis<ref>Overgaard CB and Dzavik V. Contemporary Reviews in Cardiovascular Medicine: Inotropes and Vasopressors - Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008; 118: 1047-1056.</ref> | |||
*****Preferred over pressors with beta agonism | |||
***Push dose pressor while waiting for IV drip: | |||
****Place 1mL of 10mg/mL phenylephrine in 100mL NS | |||
****Final concentration 100mcg/mL | |||
****Use 1-2mL q2-5min (100-200mcg) in 10mL syringe | |||
****Onset 1min; duration 20min | |||
===Pharmacologic Management=== | ===Pharmacologic Management=== | ||
*Per Amer Coll of Cardiology 2011 recommendations<ref>American College of Cardiology. 2011. http://content.onlinejacc.org/article.aspx?articleid=1147838</ref> | *Per Amer Coll of Cardiology 2011 recommendations<ref>American College of Cardiology. 2011. http://content.onlinejacc.org/article.aspx?articleid=1147838</ref> | ||
*Class I | *Class I | ||
** | **[[beta-blockers]] for angina or dyspnea in adults in HCM regardless of obstructive physiology - use with caution in sinus brady or conduction abnormality | ||
**Titrate BB dose to symptoms, may increase BB dose to resting HR to 60 bpm | **Titrate BB dose to symptoms, may increase BB dose to resting HR to 60 bpm | ||
**PO | **[[Verapamil]] PO titrated up to 480mg/d if patient unresponsive or cannot tolerate beta-blockers - caution in advanced HF, hypotension, sinus brady, high LVOT gradients | ||
**IV phenylephrine for acute hypotension unresponsive to fluids | **'''IV [[phenylephrine]]''' for acute hypotension unresponsive to fluids | ||
*Class IIa | *Class IIa | ||
**Reasonable to add disopyramide with BB or verapamil if unresponsive to BB or CCB alone in obstructive HCM | **Reasonable to add disopyramide with BB or verapamil if unresponsive to BB or CCB alone in obstructive HCM | ||
**Reasonable to add oral diuretics in nonobstructive HCM when symptoms persist despite BB or CCB | **Reasonable to add oral [[diuretics]] in nonobstructive HCM when symptoms persist despite BB or CCB | ||
*Class III (harm) | *Class III (harm) | ||
**Avoid nifedipine and other dihydropyridine CCB | **''Avoid'' nifedipine and other dihydropyridine CCB | ||
**Avoid digitalis | **''Avoid'' digitalis | ||
**Avoid disopyramide alone | **''Avoid'' disopyramide alone with out BB or CCB | ||
**Avoid positive inotropic vasopressors (dopamine, dobutamine, | **'''Avoid positive inotropic vasopressors''' (dopamine, dobutamine, norepinephrine, epi) | ||
==Disposition== | |||
*Admit for echo and cardiology evaluation | |||
*If unable to admit, home on β-blocker, instructions for no exertion, follow up echo and cardiology outpt | |||
==See Also== | ==See Also== | ||
*[[Cardiomyopathy]] | *[[Cardiomyopathy]] | ||
*[https://www.youtube.com/watch?v=RsNkhr4lhhU Amal Mattu July 30, 2012 case] | |||
== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Cardiology]] |
Revision as of 15:22, 25 September 2019
Background
- Genetically-linked (AD) hypertrophy of cardiac muscle - can but does not always cause outflow obstruction
- Up to 30% of patients will have no family history[1]
- Average age of diagnosis between 30-40 years of age
- Diastolic heart failure
- Abnormal LV function due to decreased compliance
- Historically, obstructive forms known as:
- Idiopathic hypertrophic subaortic stenosis (IHSS)
- Asymmetric septal hypertrophy (ASH)
- Hypertrophic obstructive cardiomyopathy (HOCM)
- Yamaguchi syndrome, an atypical HCOM, in which only 1% are non-Japanese
Clinical Features
- Syncope, chest pain, dyspnea
- Symptoms made worse by exertion
- Increasing ventricular contractility further narrows outflow as volume is lost
- Systolic murmur increases with valsalva
- Decreased blood return to heart
- Decreases with squat/fist clench
- Increased peripheral resistance increases aorta and reduces obstruction
Differential Diagnosis
Cardiomyopathy
- Dilated cardiomyopathy
- Hypertrophic cardiomyopathy
- Restrictive cardiomyopathy
- Peripartum cardiomyopathy
- Takotsubo cardiomyopathy
- Arrhythmogenic right ventricular dysplasia
Chest pain
Critical
- Acute coronary syndromes (ACS)
- Aortic dissection
- Cardiac tamponade
- Coronary artery dissection
- Esophageal perforation (Boerhhaave's syndrome)
- Pulmonary embolism
- Tension pneumothorax
Emergent
- Cholecystitis
- Cocaine-associated chest pain
- Mediastinitis
- Myocardial rupture
- Myocarditis
- Pancreatitis
- Pericarditis
- Pneumothorax
Nonemergent
- Aortic stenosis
- Arthritis
- Asthma exacerbation
- Biliary colic
- Costochondritis
- Esophageal spasm
- Gastroesophageal reflux disease
- Herpes zoster / Postherpetic Neuralgia
- Hypertrophic cardiomyopathy
- Hyperventilation
- Mitral valve prolapse
- Panic attack
- Peptic ulcer disease
- Pleuritis
- Pneumomediastinum
- Pneumonia
- Rib fracture
- Stable angina
- Thoracic outlet syndrome
- Valvular heart disease
- Muscle sprain
- Psychologic / Somatic Chest Pain
- Spinal Root Compression
- Tumor
Evaluation
- Symptoms: Syncope or sudden death most common
- Also exertional dyspnea, chest pain, syncope, dizziness, palpitations, or CHF
- Systolic murmur that increases with maneuvers that decrease preload (e.g. valsalva, transitioning from squatting to standing, etc.).
- ECG
- Nonspecific/normal.
- Or, high voltage/LVH, deep narrow Q waves in 1, avL, V5, V6 = "daggers of death"
Work-Up
- ECG abnormalities in ~90%, but mostly nonspecific
- High voltage ECG (which may produce abnormal T-waves)
- LVH
- Left atrial enlargement
- Tall R-wave in V1, mimicking posterior MI
- "Needle-like" Q waves, especially in lateral leads, mimicking infarction Q waves
- CXR may be normal as LV is non-dilated
- Echo[3]
- Unexplained wall thickness > 15 mm in any myocardial segment
- Septal/posterior wall thickness ratio:
- >1.3 in normotensive pts
- >1.5 in hypertensive pts
- Systolic anterior motion by M mode in PSL window, worsened by Valsalva
- Mitral regurgitation
- EF may be preserved until acute decompensation
- Formal echo should include tissue Doppler imaging
Management
- Avoid exertion
- ICD +/- pacer for ventricular dysrhythmias
- Definitive treatment is myomectomy
Decompensated
- Consider primary insult, which usually is preload issue (fluid depletion, bleed, etc.)
- If decompensated presents as hypotensive CHF
- Preserve preload
- Careful hydration
- Avoid high airway pressure if intubate
- Limit tachycardia
- Avoid vasodilators (no nitrates)
- Maintain sinus rhythm (i.e. cardiovert A. fib)
- Increase afterload (hypotensive only)
- Phenylephrine, max dose range depending on source
- Start at 100 mcg/min (~1.5 mcg/kg/min for average adult)
- Range usually 0.5 - 6.0 mcg/kg/min, with efficacy minimal beyond 6 mcg/kg/min)[4]
- Max phenylephrine infusion before other pressors
- Fix acid-base disorder as acidosis may prevent pressor efficacy
- Consider maxing vasopressin next
- Pressor effects more preserved in hypoxia and acidosis[5]
- Preferred over pressors with beta agonism
- Push dose pressor while waiting for IV drip:
- Place 1mL of 10mg/mL phenylephrine in 100mL NS
- Final concentration 100mcg/mL
- Use 1-2mL q2-5min (100-200mcg) in 10mL syringe
- Onset 1min; duration 20min
- Phenylephrine, max dose range depending on source
- Preserve preload
Pharmacologic Management
- Per Amer Coll of Cardiology 2011 recommendations[6]
- Class I
- beta-blockers for angina or dyspnea in adults in HCM regardless of obstructive physiology - use with caution in sinus brady or conduction abnormality
- Titrate BB dose to symptoms, may increase BB dose to resting HR to 60 bpm
- Verapamil PO titrated up to 480mg/d if patient unresponsive or cannot tolerate beta-blockers - caution in advanced HF, hypotension, sinus brady, high LVOT gradients
- IV phenylephrine for acute hypotension unresponsive to fluids
- Class IIa
- Reasonable to add disopyramide with BB or verapamil if unresponsive to BB or CCB alone in obstructive HCM
- Reasonable to add oral diuretics in nonobstructive HCM when symptoms persist despite BB or CCB
- Class III (harm)
- Avoid nifedipine and other dihydropyridine CCB
- Avoid digitalis
- Avoid disopyramide alone with out BB or CCB
- Avoid positive inotropic vasopressors (dopamine, dobutamine, norepinephrine, epi)
Disposition
- Admit for echo and cardiology evaluation
- If unable to admit, home on β-blocker, instructions for no exertion, follow up echo and cardiology outpt
See Also
References
- ↑ Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force of Practice.
- ↑ http://www.thepocusatlas.com/pediatrics/
- ↑ Mitevksa IP. Focus on echocardiography in hypertrophic cardiomyopathy - fourth in series. ESC Council for Cardiology Practice. Vol.13,N°20 - 14 Apr 2015.
- ↑ Global RPH in reference to Micromedex. 12/2014. http://www.globalrph.com/phenylephrine_dilution.htm
- ↑ Overgaard CB and Dzavik V. Contemporary Reviews in Cardiovascular Medicine: Inotropes and Vasopressors - Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008; 118: 1047-1056.
- ↑ American College of Cardiology. 2011. http://content.onlinejacc.org/article.aspx?articleid=1147838